Opioid-Induced Constipation: Update on Prevention and Management

Post Test and Evaluation Form

Please note that to receive credit you must achieve a score of at least 80%.

The information that you participated will be uploaded to CPE Monitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit http://www.nabp.net/.

Question Title

1. Among patients with chronic nonmalignant pain, what percent report OIC?

25%

40%

60%

80%

Question Title

2. Which of the following is a stimulant laxative?

Psyllium

Senna

Docusate

Magnesium sulfate

Question Title

3. Methylnaltrexone is considered a:

peripherally-acting mu-opioid receptor antagonist.

centrally-acting mu-opioid receptor antagonist.

non-specific mu-opioid receptor agonist

stimulant laxative.

Question Title

4. Lubiprostone is considered a:

sodium channel activator.

magnesium channel inhibitor.

chloride channel activator.

calcium channel inhibitor.

Question Title

5. Signs of an insufficient response to laxative therapy for OIC include all of the following except:

hard stools.

excessive straining.

having about 1 stool per day.

sense of incomplete evacuation.

Question Title

6. OIC is a risk for patients taking:

hydrocodone.

methadone.

fentanyl.

all of the above